Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083577 · ClinicalTrials.gov registry record · Phase 2
Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00083577: Completed Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00083577 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Arkansas. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083577, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/MIRT - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 1998-02 |
| Est. Completion | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00083577 record still lists
NCT00083577 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00083577 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00083577 about?
NCT00083577 is a clinical study titled "Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma". The purpose of this research is to study how helpful thalidomide is in controlling the myeloma disease and to study any side effect resulting from thalidomide.
What is the current status of trial NCT00083577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 1998-02. Estimated completion is 2005-05.
What conditions does trial NCT00083577 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00083577?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00083577?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083577 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00083577's enrollment target sits among peer trials
250 88th of 438 higher than 347 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia